Farletuzumab is a humanized monoclonal antibody that binds to GP-3 antigen and triggers a host immune response against GP-3 expressing cells. Farletuzumab has been investigated for the treatment of ovarian cancer.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.